On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.

Proceeds from the financing will primarily support the advancement of K-1728, KymaThera’s investigational, oral, pan-mutant selective PI3Kα inhibitor.

The Wilson Sonsini team that advised KymaThera on intellectual property matters related to the financing includes Deborah Smith, David Clark, and Marcos Gonzalez Lopez.

For more information, please see KymaThera’s news release. Additional coverage can be found on Pulse 2.0.